Dr. Michael Koslowski has over 20 years experience in R&D, specialising in discovery and development of immunotherapeutic drugs within academia and biopharmaceutical companies. Currently, Michael serves as Chief Medical Officer at GammaDelta Therapeutics, a London based biotech company developing novel cell therapies for immunotherapy of cancer. Prior, he was EVP R&D and Chief Medical Officer at Mission Therapeutics, where he was responsible for developing the company’s pipeline deubiquitinating enzyme inhibitors. As VP Clinical Sciences & Early Development at Glenmark Pharmaceuticals he led all clinical activities across therapeutic areas, including Glenmark’s first oncology development programme. At Boehringer Ingelheim he was Global Head of Translational Medicine Experts, responsible for building a new Translational Medicine Group from scratch. Prior to Boehringer Ingelheim, Michael was founding member and Group Leader of New Targets & Antibody Development at Ganymed Pharmaceuticals. Michael held academic positions such as Principal Scientist in Experimental and Translational Oncology at the University of Mainz and University of the Saarland. Michael has a degree in Medicine from the University of Cologne (Germany) and a habilitation degree in Molecular Medicine from the University of Mainz (Germany).